MDMA and psilocybin therapy rules have been relaxed. Here’s what might happen next
Thileepan Naren, Suzanne Nielsen, Myfanwy Graham
June 29, 2026 DOI: 10.64628/aa.ffmxwhc4v via OpenAlex
Abstract
No abstract available from the source.
Related reading
- Psilocybin's effects on obsessive-compulsive behaviors: A systematic review of preclinical and clinical evidence Psychedelics. • October 28, 2025 • via OpenAlex
- Efficacy and risks of psychedelics in treatment of posttraumatic stress disorder: A systematic review American Journal of Health-System Pharmacy • March 4, 2026 • via OpenAlex
- Psychedelics in psychiatric treatment: a literature review Quality in Sport • January 26, 2026 • via OpenAlex
- Classifying Psychedelic-Related Complications Current topics in behavioral neurosciences • January 1, 2026 • via OpenAlex
- Psilocybin as a Serotonergic Therapy in Epilepsy: Narrative Review of Therapeutic Potentials and Seizure Risks December 29, 2025 • via OpenAlex